The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 147, Issue 8, 2008, Pages 1419-1424

  Polanczyk, Guilherme ^a,b   Faraone, Stephen V ^c   Bau, Claiton H D ^a   Victor, Marcelo M ^a   Becker, Katja ^d,e   Pelz, Reta ^d   Buitelaar, Jan K ^f   Franke, Barbara ^f   Kooij, Sandra ^g   Van Der Meulen, Emma ^h   Cheon, Keun Ah ⁱ   Mick, Eric ^j   Purper Ouakil, Diane ^k,l   Gorwood, Philip ^l,m   Stein, Mark A ⁿ   Cook Jr , Edwin H ⁿ   Rohde, Luis Augusto ^a,o  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Adult ADHD Program/PsyQ   (Netherlands)

^h Academic Center for Child and Adolescent Psychiatry   (Netherlands)

ⁱ Kwandong University College of Medicine   (South Korea)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k HÔPITAL ROBERT DEBRÉ   (France)

^l INSERM   (France)

^m HÔPITAL LOUIS MOURIER   (France)

ⁿ UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^o HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

more..

Author keywords

ADHD; Meta regression; Methylphenidate; Pharmacogenetics; Treatment

Indexed keywords

METHYLPHENIDATE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COMORBIDITY; CONFOUNDING VARIABLE; DEMOGRAPHY; ETHNICITY; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; METHODOLOGY; OPPOSITIONAL DEFIANT DISORDER; PHARMACOGENETICS; PRIORITY JOURNAL; SAMPLING; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COMORBIDITY; DEMOGRAPHY; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RESEARCH DESIGN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57349085226     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30855     Document Type: Article

References (35)

1. Arnold LE, Elliot M, Sachs L, Bird H, Kraemer HC, Wells KC, Abikoff HB, Comarda A, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hindshaw SP, Hoza B, Jensen PS, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wigal T. 2003. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consult Clin Psychol 71(4):713-727.
2. Brown TE. 2006. Toward an adequate understanding of attention deficit disorders. Rev Bras Psiquiatr 28(4):261-262.
3. Buitelaar JK, Van der Gaag RJ, Swaab-Barneveld H, Kuiper M. 1995. Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34(8):1025-1032.
4. Cheon KA, Kim BN, Cho SC. 2007. Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children. Neuropsychopharmacology 32(6):1377-1383.
5. Curtin F, Altman DG, Elbourne D. 2002. Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Stat Med 21(15):2131-2144.
6. DuPaul GJ, Power TJ, Anastopoulos AD. 1998. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York: Guilford Press.
7. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. 2002. Meta-analyses involving cross-over trials: Methodological issues. Int J Epidemiol 31(1):140-149.
8. Faraone SV. 2003. Report from the 4th international meeting of the attention deficit hyperactivity disorder molecular genetics network. Am J Med Genet Part B 121B(1):55-59.
9. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. 2004. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 24(1):24-29.
10. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P. 2005. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57(11):1313-1323.
11. Faraone SV, Biederman J, Spencer TJ, Aleardi M. 2006. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 8(4):4.
12. Findling RL, Short EJ, Manos MJ. 2001. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 40(12):1441-1447.
13. Ghuman JK, Riddle MA, Vitiello B, Greenhill LL, Chuang SZ, Wigal SB, Kollins SH, Abikoff HB, McCracken JT, Kastelic E, Scharko AM, McGoughn JJ, Murray DW, Evans L, Swanson JM, Wigal T, Posner K, Cunningham C, Davies M, Skrobala AM. 2007. Comorbidity moderates response to methylphenidate in the preschoolers with attention-deficit/hyperactivity disorder treatment study (PATS). J Child Adolesc Psychopharmacol 17(5):563-580.
14. Goez H, Back-Bennet O, Zelnik N. 2007. Differential stimulant response on attention in children with comorbid anxiety and oppositional defiant disorder. J Child Neurol 22(5):538-542.
15. Goldstein DB, Tate SK, Sisodiya SM. 2003. Pharmacogenetics goes genomic. Nat Rev Genet 4:937-947.
16. Higgins J, Thompson S, Deeks J, Altman D. 2002. Statistical heterogeneity in systematic reviews of clinical trials: A critical appraisal of guidelines and practice. J Health Serv Res Policy 7(1):51-61.
17. Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, March JS, Arnold LE, Cantwell DP, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Pelham WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B. 2001. ADHD comorbidity findings from the MTA study: Comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 40(2):147-158.
18. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, Howes MJ, Jin R, Secnik K, Spencer T, Ustun TB, Walters EE. 2005. The World Health Organization Adult ADHD Self-Report Scale (ASRS): A short screening scale for use in the general population. Psychol Med 35(2):245-256.
19. Kooij JS, Boonstra AM, Vermeulen SH, Heister AG, Burger H, Buitelaar JK, Franke B. 2008. Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). Am J Med Genet Part B 147B(2):201-208.
20. Mick E, Biederman J, Spencer T, Faraone SV, Sklar P. 2006. Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD. Am J Med Genet Part B 141B(8):890-894.
21. Polanczyk G, Zeni C, Genro JP, Roman T, Hutz MH, Rohde LA. 2005. Attention-deficit/hyperactivity disorder: Advancing on pharmacogenomics. Pharmacogenomics 6(3):225-234.
22. Polanczyk G, Lima MS, Horta BL, Biederman J, Rohde LA. 2007a. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry 164(6):942-948.
23. Polanczyk G, Zeni C, Genro JP, Guimaraes AP, Roman T, Hutz MH, Rohde LA. 2007b. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 64(2):218-224.
24. Purper-Ouakil D, Orejarena S, Cortese S, Boni C, Mouren M, Gorwood P. 2008. Pharmacogenetics of methylphenidate response in Attention Deficit/Hyperactivity Disorder: Association with the dopamine transporter gene (SLC6A3). Am J Med Genet Part B, Jun 18 [Epub ahead of print].
25. Reinhardt MC, Benetti L, Victor MM, Grevet EH, Belmonte-de-Abreu P, Faraone SV, Rohde LA. 2007. Is age-at-onset criterion relevant for the response to methylphenidate in attention-deficit/hyperactivity disorder? J Clin Psychiatry 68(7):1109-1116.
26. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH. 2002. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics 12(6):497-499.
27. Stein MA, McGough MD. 2008. The pharmacogenomic era: Promise for personalizing ADHD therapy. Child Adolesc Psychiatr Clin N Am 17(2):475-490.
28. Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C, Kim SJ, Cook EH. 2005. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 30(7):1374-1382.
29. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M. 2001. Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40(2):168-179.
30. Swanson J, Schuck S, Mann M, Carlson C, Hartman K, Sergeant J, Clevenger W, Wasdell M, McCleary. 2005. Categorical and dimensional definitions and evaluations of symptoms of ADHD: The SNAP and the SWAN Ratings Scales. URL: http://www.adhd.net/SNAP_SWAN.pdf. [Accessed on 08/20/2008].
31. Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M. 1987. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med 17(1): 121-143.
32. Tharoor H, Lobos EA, Todd RD, Reiersen AM. 2007. Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. Am J Med Genet Part B 147B(4):527-530.
33. Thompson SG, Higgins JP. 2002. How should meta-regression analyses be undertaken and interpreted? Stat Med 21(11):1559-1573.
34. van der Meulen EM, Bakker SC, Pauls DL, Oteman N, Kruitwagen CL, Pearson PL, Sinke RJ, Buitelaar JK. 2005. High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD. J Child Psychol Psychiatry 46(10):1074-1080.
35. Zeni CP, Guimaraes AP, Polanczyk GV, Genro JP, Roman T, Hutz MH, Rohde LA. 2007. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. Am J Med Genet Part B 144B(3):391-394.